IDEXX Laboratories, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Erickson
- Full Time Employees
- 11,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- One IDEXX Drive Westbrook ME United States of America 04092
- IPO Date
- Jun 21, 1991
- CIK
- 0000874716
- Website
- idexx.com
- Similar Companies
- Business
- IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes diagnostic products, equipment, and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. The company offers an extensive portfolio of in-clinic analyzers including the Catalyst One Chemistry Analyzer, ProCyte Dx Hematology Analyzer, SediVue Dx Urine Sediment Analyzer, and SNAP point-of-care tests; reference laboratory services for advanced diagnostics; veterinary software solutions such as IDEXX Neo and Cornerstone practice management software, VetLab Station laboratory information management system, and client communication tools; diagnostic imaging systems like ImageVue DR50 and EliteVision; and specialized tests for ruminants (e.g., BVDV, IBR/BHV-1, Johne's Disease), poultry (e.g., IBV, IBD), swine (e.g., PRRS, PEDV), equine health (e.g., EHV-1/4 RealPCR, EPM tests), and water quality microbiological detection serving over 2.5 billion people. IDEXX also provides OPTI Medical Systems for human point-of-care and laboratory diagnostics. Founded in 1983 and headquartered in Westbrook, Maine, the company operates in over 175 countries through its three main segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD), with additional EMEA headquarters in Hoofddorp, Netherlands, and approximately 10,000 employees worldwide. Recent developments include the strong adoption of the inVue Dx Cellular Analyzer with over 2,400 units installed in Q2 2025, surpassing expectations and prompting a full-year installation forecast increase to 5,500 units; the June 2025 launch of the Catalyst Cortisol Test, the third Catalyst platform expansion that year, enhancing point-of-care diagnostics for endocrine disorders like Addison's and Cushing's disease in dogs; the North American rollout of IDEXX Cancer Dx; upward revisions to 2025 revenue guidance to $4.27 billion-$4.30 billion and EPS to $12.81-$13.01 amid 11% Q2 revenue growth and 13% Q3 growth driven by recurring CAG diagnostics; and sustained R&D investment at about 5.75% of revenue to support platform expansions, AI-driven solutions, molecular tests, international commercial footprint growth in three countries by 2026, and software enhancements.
Company News
Baron Focused Growth Fund Q2 2026 Portfolio Update
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?
American Capital Management Inc. Acquires Shares of 162,110 IDEXX Laboratories, Inc. $IDXX
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
IDEXX Laboratories: Worth The Premium
Aurora Investment Managers LLC. Makes New Investment in IDEXX Laboratories, Inc. $IDXX
Here is Why Growth Investors Should Buy Idexx (IDXX) Now
IDEXX Laboratories, Inc. $IDXX Shares Sold by Empowered Funds LLC
IDEXX Laboratories Q2 Earnings Call Highlights
IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amidst Persistent Visit Headwinds
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market